Clinical Trials Browser

INDUSTRY × Recurrence × pirtobrutinib × Clear all

NCT07342478 2026-01-16

ROCKET-CLL Global Phase 3 Study: Rocbrutinib vs Pirtobrutinib in cBTKi-Pretreated R/R CLL/SLL

Phase 3 Not yet recruiting

LymphoidOther hematologic neoplasm

Chromosome 17 deletion, Recurrence, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell